PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAlemtuzumab
Campath , Mabcampath(alemtuzumab)
Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Campath (discontinued: Campath)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alemtuzumab
Tradename
Proper name
Company
Number
Date
Products
LemtradaalemtuzumabSanofiN-103948 RX2014-11-14
1 products
Campath alemtuzumabSanofiN-103948 RX2004-10-12
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
campathBiologic Licensing Application2024-12-11
lemtradaBiologic Licensing Application2024-05-21
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration
Code
alemtuzumab, Campath , Genzyme Corporation
2108-05-07Orphan excl.
alemtuzumab, Lemtrada, Genzyme Corporation
2108-05-07Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA34: Alemtuzumab
HCPCS
Code
Description
J0202
Injection, alemtuzumab, 1 mg
Clinical
Clinical Trials
389 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G352266520
SclerosisD0125982265418
Relapsing-remitting multiple sclerosisD020529EFO_0003929144110
Nerve degenerationD00941011
Chronic inflammatory demyelinating polyradiculoneuropathyD020277EFO_1000868G61.8111
PolyradiculoneuropathyD011129EFO_100111611
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C95472314
Lymphoid leukemiaD007945C91352211
B-cell chronic lymphocytic leukemiaD015451C91.1242210
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.9445
Non-hodgkin lymphomaD008228C85.9323
Myelodysplastic syndromesD009190D46111
Myeloid leukemia acuteD015470C92.0111
Myeloid leukemiaD007951C92111
PreleukemiaD011289111
Prolymphocytic leukemia t-cellD015461C91.611
Prolymphocytic leukemiaD01546311
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0111
T-cell lymphomaD016399111
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403C83.311
B-cell lymphomaD01639311
Chronic progressive multiple sclerosisD020528EFO_000384011
Graft vs host diseaseD006086D89.8111
Hematologic neoplasmsD01933711
NeoplasmsD009369C8011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell leukemiaD01544811
Covid-19D000086382U07.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlemtuzumab
INNalemtuzumab
Description
Immunoglobulin G 1 (human-rat monodonal CAMPATH-1H 71-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>1CE1:H|PROTEIN (CAMPATH-1H:HEAVY CHAIN) QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQ FSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1CE1:L|PROTEIN (CAMPATH-1H:LIGHT CHAIN) DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQP EDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
Identifiers
PDB1BEY, 1BFO, 1CE1, 6OBD
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201587
ChEBI ID
PubChem CID
DrugBankDB00087
UNII ID3A189DH42V (ChemIDplus, GSRS)
Target
Agency Approved
CD52
CD52
Organism
Homo sapiens
Gene name
CD52
Gene synonyms
CDW52, HE5
NCBI Gene ID
Protein name
CAMPATH-1 antigen
Protein synonyms
Cambridge pathology 1 antigen, CD52, CD52 antigen (CAMPATH-1 antigen), CDw52, CDW52 antigen (CAMPATH-1 antigen), Epididymal secretory protein E5, epididymis secretory sperm binding protein Li 171mP, He5, HEL-S-171mP, Human epididymis-specific protein 5
Uniprot ID
Mouse ortholog
Cd52 (23833)
CAMPATH-1 antigen (Q64389)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,996 documents
View more details
Safety
Black-box Warning
Black-box warning for: Campath, Lemtrada
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18,674 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use